NCT05286801 2026-05-13Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)Phase 1/2 Active not recruiting86 enrolled